17:16:08 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Medicenna Therapeutics Corp
Symbol MDNA
Shares Issued 92,300,201
Close 2026-11-16 C$ 0.365
Market Cap C$ 33,689,573
Recent Sedar+ Documents

Medicenna upbeat about phase 2b results for bizaxofusp

2026-11-16 16:56 ET - News Release

Dr. Fahar Merchant reports

MEDICENNA REPORTS MORE THAN DOUBLING OF MEDIAN OVERALL SURVIVAL IN GLIOBLASTOMA PATIENTS WITH UNRESECTABLE RECURRENT IDH-WT TUMORS FOLLOWING ONE TREATMENT WITH BIZAXOFUSP VERSUS A MATCHED EXTERNAL CONTROL AT SNO 2026

Medicenna Therapeutics Corp. is releasing clinical results from the phase 2b study of bizaxofusp (formerly MDNA55) in patients with unresectable recurrent glioblastoma (rGBM). The data were presented during an oral session at the 31st annual meeting of the Society for Neuro-Oncology (SNO 2026), held in Philadelphia from Nov. 12 to Nov. 15, 2026.

The presentation, titled "Survival outcomes with bizaxofusp (MDNA55) in unresectable IDH-wildtype recurrent glioblastoma (rGBM) using a propensity score-weighted external control arm (ECA) in the intended phase 3 population," was delivered by Nicholas A. Butowski, MD, professor of neurological surgery and director of Translational Research, Neuro-Oncology at the University of California, San Francisco.

"These results provide important evidence that further strengthens the potential of bizaxofusp for patients with unresectable recurrent glioblastoma, a population with few effective treatment options and a median survival of six to seven months," said Fahar Merchant, PhD, president and chief executive officer of Medicenna. "Most importantly, the magnitude of the observed survival effect was greatest in the patient population that most closely reflects our planned phase 3 treatment strategy, where median overall survival more than doubled compared with a stringently matched and independently analyzed external control. Together with our prior discussions with the FDA, these results further strengthen the clinical rationale for advancing bizaxofusp toward a pivotal study using a hybrid randomized phase 3 design. We look forward to advancing bizaxofusp's development in collaboration with potential partners."

The external control analysis included 80 eligibility-matched records obtained from patient registries at UCSF and St. Michael's Hospital, including 79 patients with confirmed IDH-wildtype disease. Overall survival was measured from the same clinical index date in both the bizaxofusp and external-control populations, and propensity score weighting was re-estimated for each comparison. The phase 3-relevant comparison is based on a small subgroup (N=19). Retrospective external-control comparisons remain susceptible to residual confounding and are not a substitute for randomized evidence.

"Recurrent glioblastoma remains extremely challenging to treat, particularly for patients who are not candidates for repeat surgery," said Dr. Butowski. "The survival difference observed with bizaxofusp relative to a carefully matched external control is encouraging, particularly in the high-dose IDH-wildtype group that most closely reflects the intended phase 3 population. This is a non-randomized comparison in a small number of patients and needs to be confirmed, but these findings provide a strong rationale to evaluate bizaxofusp prospectively in a randomized pivotal study."

Key findings presented at SNO 2026

Median overall survival was more than twice that of the external control in the phase 3-relevant population.

Among confirmed IDH-wildtype patients treated with at least 180 micrograms of bizaxofusp (N=19), mOS was 13.7 months compared with 6.2 months for the eligibility-matched and propensity score-balanced ECA (HR 0.499; 95 per cent CI: 0.278-0.895; p=0.013). Twelve-month survival was 52.6 per cent with bizaxofusp compared with 15.6 per cent for the ECA, while 24-month survival was 26.3 per cent compared with 6.7 per cent, respectively.

The survival difference favouring bizaxofusp was maintained in the broader WHO-aligned IDH-wildtype population. In all confirmed IDH-wildtype patients in the per-protocol population (N=37), mOS was 12.5 months with bizaxofusp compared with 7.3 months for the ECA (HR 0.625; 95 per cent CI: 0.393-0.993; p=0.043), including patients receiving low doses of bizaxofusp (less than 180 micrograms).

A consistent survival difference was observed in the per-protocol population (N=44), where mOS was 12.5 months with bizaxofusp compared with 7.2 months for the ECA (HR 0.621; 95 per cent CI: 0.413-0.934; p=0.023), including patients with unknown IDH status and low dose cohorts

Propensity score weighting achieved strong balance between treatment and control populations. The external control analysis balanced patients across 10 established prognostic factors in recurrent GBM, including age, sex, performance status, MGMT promoter methylation, time to relapse, prior relapses, extent of initial resection, tumour size and location at relapse, and steroid use. In the phase 3-relevant comparison, all prognostic factors and the propensity score had absolute standardized differences below 0.10, demonstrating negligible measured baseline imbalance between the bizaxofusp arm and ECA.

Results support the planned phase 3 dose and patient population. The high-dose analysis included an IL-4R-unselected population of patients with confirmed IDH-wildtype disease receiving at least 180 micrograms of bizaxofusp. The planned phase 3 dose is 240 micrograms, the established maximum tolerated dose.

Proposed phase 3 study

Medicenna's proposed pivotal study will evaluate a single 240-microgram dose of bizaxofusp administered by convection-enhanced delivery (CED) in patients with unresectable, confirmed IDH-wildtype recurrent glioblastoma at first or second recurrence.

The proposed hybrid design incorporates approximately 200 randomized patients, with approximately 150 patients receiving bizaxofusp and approximately 50 receiving standard-of-care therapy. The randomized standard-of-care arm would be supplemented by an approximately 100-patient-equivalent contemporaneous, eligibility-matched and propensity score-weighted external control arm. The primary end point is overall survival versus the hybrid control arm.

At an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), the agency agreed that a randomized standard-of-care arm supplemented by an eligibility-matched external control arm was a feasible approach for the planned pivotal study. No IL-4R companion diagnostic is planned for phase 3 eligibility, enabling enrolment irrespective of tumour IL-4R expression.

The presentation will be available on the scientific presentations section of Medicenna's investor relations website.

About Bizaxofusp

Bizaxofusp (formerly MDNA55) is Medicenna's IL-4 empowered superkine that has been evaluated in more than 130 patients across five clinical trials, including a phase 2b study in unresectable recurrent glioblastoma. Bizaxofusp is designed to selectively target the interleukin-4 receptor (IL-4R), which is overexpressed by glioblastoma cells and cells in the tumour microenvironment, and is administered directly into the tumour using convection-enhanced delivery. Bizaxofusp has received Fast Track designation from the U.S. Food and Drug Administration and Orphan Drug designation in the United States and Europe.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer and autoimmune diseases. Medicenna is advancing MDNA11, a long-acting IL-2 superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the phase 1/2 Ability-1 study and the phase 1b NEO-CYT study.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.